← Back to headlines
UCB's Bimzelx Outperforms AbbVie's Skyrizi in Psoriatic Arthritis Trial
UCB announced that its drug Bimzelx demonstrated superior efficacy compared to AbbVie's Skyrizi in a clinical trial for psoriatic arthritis.
19 May, 13:52 — 19 May, 13:52
Sources
Showing 1 of 1 sources
Related Stories
Tiger Woods Pleads Guilty to Reckless Driving, Faces Five-Year License Suspension
21m ago
USS Abraham Lincoln docks in Thailand after record 286-day deployment
26m ago
EU and NATO Condemn Failed Drone Attack at Leipzig Airport Linked to Russia
30m ago
Czech Police Exhume Remains of Foreign Minister Jan Masaryk
33m ago